Another drug study flops at AstraZeneca as CEO braces for bumpy turnaround

John Carroll In an interview with Reuters yesterday, CEO Pascal Soriot warned that turning around AstraZeneca is going to require a lengthy rebuilding effort. FierceBiotech News

Astex Pharmaceuticals Announces Presentation of Updated Results of SGI-110-01 Study

barbara.lempert Astex Pharmaceuticals Announces Presentation of Updated Results of SGI-110-01 Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic ...

AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199

barbara.lempert AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia ...

Lilly Ends Phase II Alzheimer’s Study Over Liver Problems

barbara.lempert Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer’s Disease Decision ...

Lilly’s oral rheumatoid arthritis blockbuster contender champions 1-year study

John Carroll Efficacy results for an experimental rheumatoid arthritis drug in development by Eli Lilly and Incyte held up well as patients in a Phase IIb trial were tracked over the ...

Trius Therapeutics Announces Publication of Antibiotic Safety Study

barbara.lempert Trius Therapeutics Announces Publication of Antibiotic Safety Study in Antimicrobial Agents and Chemotherapy Peer-Reviewed Results Suggest No Clinically Significant ...

Diabetes Drugs Under Scrutiny As FDA Considers Another Study

esilverman As a two-day NIH workshop gets underway to examine the safety of several widely used diabetes drugs, the FDA is considering whether to run a study to determine whether ...

Simponi Study: Majority of Patients Experience 20% Improvement

barbara.lempert Five-Year SIMPONI Data Reported In Treatment Of Signs And Symptoms Of Moderately To Severely Active Rheumatoid Arthritis Data from Three Pivotal Phase 3 Trials ...

90Y-Epratuzumab Study Shows Improvement of Therapy Results Following R-CHOP

barbara.lempert VANCOUVER, British Columbia, June 10, 2013 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development ...

FDA blasts Aveo one last time for “uninterpretable” cancer study

John Carroll FierceBiotech News

Avalere Study Shows Patients with Medicare Part D Have More Difficulty Getting Anticonvulsant Therapy

mia.burns Avalere Study Shows Patients with Medicare Part D Have More Difficulty Getting Anticonvulsant Therapy Than Those Commercially Insured Washington, D.C. – According to a ...

Study: Medicare Part D patients struggle more attaining anticonvulsants

mia.burns By Mia Burns New analysis from advisory services company Avalere Health indicates that despite anticonvulsants’ protected class status, Medicare prescription drug plans ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS